Handelsbanken Fonder’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Handelsbanken Fonder’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-25,000	Closed	-$308K	–	253
2016 Q2	$308K	Hold	25,000	–	–	0.01%	181
2016 Q1	$253K	Buy	+25,000	New	+$294K	0.01%	212

Other funds holding OMED

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Handelsbanken Fonder's OMED Position: Q3 2016 in Review

Handelsbanken Fonder sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2016, closing a stake of 25,000 shares — an estimated $308K sold.

Handelsbanken Fonder first reported a position in OMED in Q1 2016 and held it in 2 quarters. The position peaked at $308K in Q2 2016. 89 funds tracked by Wall St. Rank hold OMED as of Q3 2016.

Handelsbanken Fonder reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
Handelsbanken Fonder sold 25,000 OncoMed Pharmaceuticals, Inc. shares in Q3 2016, an estimated $308K.
Handelsbanken Fonder first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2016 and held it in 2 quarters.
Handelsbanken Fonder's OncoMed Pharmaceuticals, Inc. position peaked at $308K in Q2 2016.
89 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2016.

Based on Handelsbanken Fonder's 13F filing for Q3 2016, filed 14 Nov 2016.